- Home
- HYI vs ALDX Comparison
HYI vs ALDX Comparison
Compare HYI & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYI
- ALDX
- Stock Information
- Founded
- HYI 2010
- ALDX 2004
- Country
- HYI United States
- ALDX United States
- Employees
- HYI N/A
- ALDX N/A
- Industry
- HYI Investment Managers
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- HYI Finance
- ALDX Health Care
- Exchange
- HYI Nasdaq
- ALDX Nasdaq
- Market Cap
- HYI 272.7M
- ALDX 313.4M
- IPO Year
- HYI N/A
- ALDX 2014
- Fundamental
- Price
- HYI $11.64
- ALDX $5.60
- Analyst Decision
- HYI
- ALDX Strong Buy
- Analyst Count
- HYI 0
- ALDX 2
- Target Price
- HYI N/A
- ALDX $9.50
- AVG Volume (30 Days)
- HYI 50.6K
- ALDX 715.8K
- Earning Date
- HYI 01-01-0001
- ALDX 11-06-2025
- Dividend Yield
- HYI 9.59%
- ALDX N/A
- EPS Growth
- HYI N/A
- ALDX N/A
- EPS
- HYI N/A
- ALDX N/A
- Revenue
- HYI N/A
- ALDX N/A
- Revenue This Year
- HYI N/A
- ALDX N/A
- Revenue Next Year
- HYI N/A
- ALDX $36.23
- P/E Ratio
- HYI N/A
- ALDX N/A
- Revenue Growth
- HYI N/A
- ALDX N/A
- 52 Week Low
- HYI $10.99
- ALDX $1.14
- 52 Week High
- HYI $12.24
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- HYI 36.43
- ALDX 59.73
- Support Level
- HYI $11.47
- ALDX $5.13
- Resistance Level
- HYI $11.73
- ALDX $5.78
- Average True Range (ATR)
- HYI 0.10
- ALDX 0.23
- MACD
- HYI -0.03
- ALDX 0.06
- Stochastic Oscillator
- HYI 25.31
- ALDX 84.00
About HYI Western Asset High Yield Defined Opportunity Fund Inc.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.